EU Research and Non Clinical Safety, R&D, Sanofi Pasteur, Campus Mérieux, 69280 Marcy l'Etoile, France.
Assistant Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University, Division of Infectious Diseases, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware 19803.
Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12):a029454. doi: 10.1101/cshperspect.a029454.
Pertussis is resurgent in some countries, particularly those in which children receive acellular pertussis (aP) vaccines in early infancy and boosters later in life. Immunologic studies show that, whereas whole-cell pertussis (wP) vaccines orient the immune system toward Th1/Th17 responses, acellular pertussis vaccines orient toward Th1/Th2 responses. Although aP vaccines do provide protection during the first years of life, the change in T-cell priming results in waning effectiveness of aP as early as 2-3 years post-boosters. Although other factors, such as increased virulence of pertussis strains, better diagnosis, and better surveillance may play a role, the increase in pertussis appears to be the result of waning immunity. In addition, studies in baboon models, requiring confirmation in humans, show that aP is less able to prevent nasopharyngeal colonization of than wP or natural infection.
百日咳在一些国家重新出现,特别是那些在婴儿早期接种无细胞百日咳(aP)疫苗、后期接种加强针的国家。免疫研究表明,全细胞百日咳(wP)疫苗使免疫系统向 Th1/Th17 反应方向发展,而无细胞百日咳疫苗则向 Th1/Th2 反应方向发展。虽然 aP 疫苗在生命的头几年确实提供了保护,但 T 细胞的这种初始变化导致 aP 在加强针接种后 2-3 年内的效果逐渐减弱。尽管其他因素,如百日咳菌株的毒力增加、更好的诊断和更好的监测可能也发挥了作用,但百日咳的增加似乎是免疫减弱的结果。此外,在狒狒模型中的研究,需要在人类中得到证实,表明 aP 预防鼻咽部定植的能力比 wP 或自然感染要差。